Hamilton Global Opportunities plc (ALHGO.PA) publie ses résultats financiers du premier semestre 2026

Hamilton Global Opportunities reported net assets of €24.95 million at 30 June 2026, up 20.5% year-on-year, while cash and short-term financial investments rose to €4.87 million from €0.69 million, primarily following the sale of most of its MIAX stake. The pre-tax loss narrowed to €1.28 million from €2.58 million in H1 2025, though Gauzy Ltd's persistent underperformance and ongoing litigation in France and Israel remained a material drag. Hamilton paid a €3.44-per-share dividend (€2.17 million total; 8.0% yield) and stated that liquidity is sufficient to meet the $3.1 million bond maturity due in October 2026.

Analysis

The key equity question is not headline NAV growth but realizability: most residual value sits in illiquid, management-marked investments, while the monetizable MIAX stake has already been substantially reduced. Incremental funding into AntariaPharma and Exos Financial may protect portfolio-company growth, but it also shifts HGO from a distribution/realization story back toward a capital-allocation and valuation-mark risk. The larger liquid reserve limits near-term distress, yet refinancing or extending the October debt creates a potential dilution-versus-leverage decision within weeks, not years.

GAUZ remains the principal observable downside transmission channel. Litigation can impair customer confidence, financing access and valuation independently of operating execution; because it is the only clearly marked public portfolio holding, further weakness can expose the gap between reported NAV and exit value over the next 1-3 months. The FX benefit should not be extrapolated: USD-denominated debt offsets part of the USD-asset uplift, and the unhedged net exposure is not disclosed. Consensus may over-credit the dividend as recurring capital return; absent another realized exit, a repeat payout would likely require either asset sales at acceptable marks or added balance-sheet risk.

There is no clean directional trade in ALHGO without current share price, shares outstanding, NAV per share, average daily liquidity, and the current discount/premium to NAV. A sustained discount materially wider than the cash-adjusted, independently supportable NAV discount would be the only attractive catalyst-driven setup; conversely, a premium to reported NAV is difficult to justify given concentration, litigation and private-mark uncertainty.

Key Decisions for Investors

• Do not initiate ALHGO.PA exposure before verifying NAV per share, trading liquidity and the market discount to NAV; place an alert for the October 2026 debt decision. Prefer a small long only if the shares trade at a >35% discount to NAV after applying a conservative 25-30% haircut to private investments, with the refinancing outcome as the 1-3 month catalyst.
• Maintain a negative bias on GAUZ over the next 1-3 months, preferably via a borrow-available short or put structure only after confirming borrow cost and liquidity. Thesis is falsified by a credible litigation resolution, fully funded liquidity runway, or operating guidance that demonstrates customer retention despite legal overhang.
• Treat any ALHGO price strength following the results as an opportunity to reduce rather than chase unless management discloses third-party valuation evidence for AntariaPharma/Exos and a specific debt repayment or conversion plan. The risk/reward improves only after realization events, not additional portfolio-company funding.
• No actionable MIAX or ENX position follows from this disclosure: MIAX monetization is largely historical and ENX is a listing venue rather than a direct economic beneficiary.